Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial

Safe and effective vaccines are still urgently needed to cope with the ongoing COVID-19 pandemic. Recently, we developed a recombinant COVID-19 vaccine (V-01) containing fusion protein (IFN-PADRE-RBD-Fc dimer) as antigen verified to induce protective immunity against SARS-CoV-2 challenge in pre-clin...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuyi Liao, Yuan Li, Rongjuan Pei, Xin Fang, Peiyu Zeng, Renfeng Fan, Zhiqiang Ou, Jinglong Deng, Jian Zhou, Wuxiang Guan, Yuanqin Min, Fei Deng, Hua Peng, Zheng Zhang, Chunyan Feng, Baobao Xin, Jianfeng He, Zhongyu Hu, Jikai Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Emerging Microbes and Infections
Subjects:
COVID-19
Phase I
clinical trial
recombinant protein vaccine
RBD dimer
safety
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2021.1951126
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2021.1951126

Similar Items